ERBB2 and cancer: The GLOW trial is a phase III study comparing zolbetuximab + CAPOX (capecitabine + oxaliplatin) with placebo + CAPOX as a first-line therapy in patients with Claudin18.2-positive, HER2-negative, advanced G/GEJ cancer.